152 related articles for article (PubMed ID: 14567029)
21. Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Behrenbruch C; Hollande F; Thomson B; Michael M; Warrier SK; Lynch C; Heriot A
ANZ J Surg; 2017 Sep; 87(9):665-670. PubMed ID: 28664645
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
[TBL] [Abstract][Full Text] [Related]
23. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis.
Delotte J; Desantis M; Frigenza M; Quaranta D; Bongain A; Benchimol D; Bereder JM
Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():111-4. PubMed ID: 24300558
[TBL] [Abstract][Full Text] [Related]
24. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
[TBL] [Abstract][Full Text] [Related]
25. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
28. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.
Shen P; Levine EA; Hall J; Case D; Russell G; Fleming R; McQuellon R; Geisinger KR; Loggie BW
Arch Surg; 2003 Jan; 138(1):26-33. PubMed ID: 12511145
[TBL] [Abstract][Full Text] [Related]
29. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
Elias D; Mariani A; Cloutier AS; Blot F; Goéré D; Dumont F; Honoré C; Billard V; Dartigues P; Ducreux M
Eur J Surg Oncol; 2014 Nov; 40(11):1467-73. PubMed ID: 25086990
[TBL] [Abstract][Full Text] [Related]
30. Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives.
Chauffert B; Favoulet P; Polycarpe E; Duvillard C; Beltramo JL; Bichat F; Rat P; Genne P; Benoit L
Surg Oncol Clin N Am; 2003 Jul; 12(3):835-48. PubMed ID: 14567035
[TBL] [Abstract][Full Text] [Related]
31. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
32. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.
Glehen O; Gilly FN
Surg Oncol Clin N Am; 2003 Jul; 12(3):649-71. PubMed ID: 14567023
[TBL] [Abstract][Full Text] [Related]
33. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J
J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728
[TBL] [Abstract][Full Text] [Related]
34. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
35. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies.
Katz MH; Barone RM
Surg Oncol Clin N Am; 2003 Jul; 12(3):673-88. PubMed ID: 14567024
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis.
Beaujard AC; Glehen O; Caillot JL; Francois Y; Bienvenu J; Panteix G; Garbit F; Grandclément E; Vignal J; Gilly FN
Cancer; 2000 Jun; 88(11):2512-9. PubMed ID: 10861427
[TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.
Glehen O; Cotte E; Schreiber V; Sayag-Beaujard AC; Vignal J; Gilly FN
Br J Surg; 2004 Jun; 91(6):747-54. PubMed ID: 15164446
[TBL] [Abstract][Full Text] [Related]
38. [Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis].
Lim C; Tordjmann D; Gornet JM; Nemeth J; Valleur P; Pocard M
Bull Cancer; 2010 Sep; 97(9):1053-60. PubMed ID: 20693116
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.
Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G
Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to Mitomycin C.
Rouers A; Laurent S; Detroz B; Meurisse M
Acta Chir Belg; 2006; 106(3):302-6. PubMed ID: 16910003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
